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Biomimetic insulin-imprinted polymer nanoparticles 
as a potential oral drug delivery system*
In this study, we investigate molecularly imprinted poly-
mers (MIPs), which form a three-dimensional image of the 
region at and around the active binding sites of pharma-
ceutically active insulin or are analogous to b cells bound 
to insulin. This approach was employed to create a well-
defined structure within the nanospace cavities that make 
up functional monomers by cross-linking. The obtained 
MIPs exhibited a high adsorption capacity for the target 
insulin, which showed a significantly higher release of in-
sulin in solution at pH 7.4 than at pH 1.2. In vivo studies on 
diabetic Wistar rats showed that the fast onset within 2 h is 
similar to subcutaneous injection with a maximum at 4 h, 
giving an engaged function responsible for the duration of 
glucose reduction for up to 24 h. These MIPs, prepared as 
nanosized material, may open a new horizon for oral insu-
lin delivery.
Keywords: molecularly imprinted polymers, insulin, 
nanoparticles, islet cells, oral drug delivery
Biomimetic materials are attractive agents that demonstrate the importance of inher-
ent properties of efficiently delivering drugs to desired sites in the biological system (1). 
Recent evidence has shown that nanoparticles have a potential for delivering proteins, 
since they can offer protection from the digestive proteins in the gastrointestinal (GI) en-
vironment and provide biomacromolecule passage at the desired adsorption sites within 
the GI tract for systemic drug delivery (2). Molecularly imprinted polymers (MIPs) can 
serve as good drug delivery agents especially for peptides/proteins due to their high sta-
bility, drug loading capabilities and ease of preparation (3). Biomimetic systems using 
MIPs involve the nanoparticle-biomolecule association that can produce actual interac-
tions between the initial templates and simulate biological recognition just as it does in 
replication (4). Furthermore, the use of nanoparticles in molecular imprinting on poly-
merization materials can be achieved with biomimetic carriers, including core-shell 
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lecular imprinting, self-association of polymer nanoparticles with the template has pro-
duced multiple binding site points for the recognition of biologically important macromo-
lecules within three dimensions of the polymer chains surrounding them (7). The MIPs 
designed with the coordinative effect of functional groups in the polymeric chain can bind 
a short peptide with high affinity (8). It has the preponderance of the uptake of protein 
structure on the lipid-protein bilayer, which is not only the binding affinity under the 
conditions but also the diversity of cell activities, reflecting the surface properties such as 
charge, chemical groups, and hydrophobic effect. A major advantage of molecular imprint-
ing by precipitation polymerization is that it creates a selective nanoscale environment 
with increased affinity of specific functional groups at recognition sites that mimic the 
structure of the cell membrane surface layer. The possibility of differently targeted delivery 
by the imprinting approach, not just an alternative in enhancing selective drug delivery 
but the opportunity of being used as the key of biomolecule recognition, impacted the 
uptake of the drug or biomolecule into the cells (9). Nevertheless, good design of MIPs 
suitable for protein delivery still remains a challenge.
Insulin administered into the body can cause hypoglycemia or affect the elevated 
glucose level during transport via the route of administration into muscle cells and tissues. 
Insulin is typically administered through a subcutaneous route involving the risk of pain, 
infection, hyperinsulinemia, and deposition of fat around the injection site, which often 
leads to poor patient compliance (10). Therefore, oral delivery of insulin is of great interest 
owing to the benefit of an appropriate release rate of the payload in the GI tract over an 
extended period of time. In addition, insulin transport from the site of action needs to be 
investigated with the specific target of the lipid-protein or membrane assembly at the site. 
A previous report described the interaction of the exogenous insulin with the insulin re-
ceptor contained in rat pancreatic islets (11). In this work, we exploited molecular imprint-
ing for generation of recognition sites of insulin binding to cell membranes of the islets. It 
is interesting to study the molecules and receptors present in the islets as imprinting tem-
plates for insulin binding. To our knowledge, no isolated/digested islets have been ex-
plored as an imprinting template in the literature. Exploiting the cross-linked N,N-methy-
lene-bisacrylamide (MBAA) nanoparticles prepared from a single and mixed functional 
monomer of methacrylic acid (MAA) and N-hydroxyethyl acrylamide (HEAA) copolymer 
allows reversible complexation on MIP binding sites that emerged from the intrinsic prop-
erty of a protein drug. Furthermore, the property of template imprinting on the polymer 
nanoparticle can affect the cellular uptake into blood circulation (12). The varying of ratios 
of the functional monomer and cross-linker can improve the selectivity and allow for 
specific adsorption of the insulin at the imprint site of the polymer. MIP nanoparticle-
based carriers may enable the protection of the protein from degradation and its passage 
through the absorption barrier.
The goal of this work is to synthesize MBAA cross-linked nanoparticles consisting of 
different functional groups that will interact with the template. MAA exhibits mucoadhe-
sive properties at higher concentrations (13) and the added HEAA functional monomer is 
a hydrophilic nonionic monomer with adhesive characteristics during the polymerization 
procedure (14) and thus can be anchored on the cross-linked chains of insulin-MIPs. Pre-
cipitation polymerization is a common technique for producing spherical particles with 
controlled size distribution (15). Pan et al. used precipitation polymerization for the prepa-
ration of protein-imprinted nanoparticles (16). The other advantages of this method are 
easy preparation, without addition of surfactants or stabilizers. This polymerization will 
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form individual molecules via non-covalent interactions from a very specific functionality 
through the nanoparticle-protein association so that it can help improve the protein load-
ing and delivery efficiency. The paper describes the preparation of a biomimetic insulin 
MIP-based nanocarrier for drug delivery.
EXPERIMENTAL
Materials
Methacrylic acid (MAA), N-hydroxyethyl acrylamide (HEAA), N,N-methylene-bi-
sacrylamide (MBAA), polycaprolactone triol (PCL-T), collagenase, streptozotocin, and re-
combinant human insulin expressed in yeasts (proprietary host) were purchased from 
Sigma-Aldrich (USA). 2,2′-Azobis-(isobutyronitrile) (AIBN) was supplied by Wako Pure 
Chemical Industries Ltd. (Japan). MAA was distilled before use. Human insulin (recombi-
nant DNA origin; 100 IU/mL) was from Eli Lilly Asia, Inc., (Humulin® N) and Novo Nord-
isk Pharma, Thailand (Insulatard® HM). All other reagents were of analytical grade and 
were used as received.
Preparation of molecularly imprinted nanoparticles
Insulin-imprinted nanoparticles were prepared by the precipitation polymerization 
method (17) using MBAA as a cross-linker in the presence of insulin or islet-bound insulin 
as the template in aqueous medium. The template and functional monomer mole ratio var-
ied from 1:4 to 1:12 (Table I). Typically, MAA (1.6 mmol), HEAA (2.0 mmol), MBAA (8.5 
mmol), insulin (35 mg), PCL-T (0.05 mmol), and phosphate-buffered saline (PBS; 10 mL) as 
a porogenic solvent were added into a 30 mL vial. After 30 min of stirring, a clear solution 
was obtained, to which AIBN (0.04 mmol) was added. The vial was then purged with nitro-
gen and polymerized under a UV lamp at 254 nm wavelength for 12 h at room temperature 
(25 °C). At low temperature, the decomposition of AIBN was lower and produced low effi-
cacy of free radicals, which affected the double-bond conversion of the formed product. 
Nonetheless, the appropriate duration of polymerization that provided the formed polymer 
product was determined by infrared (IR) spectroscopy. Monomers are water soluble; how-
ever, the solubility decreases due to the formation of oligomers during polymerization and 
the monomers are finally precipitated. The resultant insulin-imprinted polymers were col-
lected by centrifugation at 10,000 rpm for 5 min. After that, the adsorbed oligomers and 
unreacted monomers were removed from the MIP by washing with Milli-Q water. To re-
move the embedded insulin molecules from the polymer matrix, MIP nanoparticles were 
subsequently washed several times at room temperature with 0.5 mol L–1 NaCl solution and 
Milli-Q water, and insulin removal from the prepared MIPs was tested using a UV-Vis 
spectrophotometer and analyzing the supernatant at the maximum wavelength (272 nm). 
Likewise, the non-imprinted polymer (NIP) nanoparticles were synthesized and washed, 
except for the omission of the template protein during the polymerization process.
Isolation of rat pancreatic islets
Wistar rats (200–250 g average body mass) were obtained from the Southern Laboratory 
Animal Facilities of the Prince of Songkla University. Experimental animals were maintained 
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on a dry pellet diet and water ad libitum. Rats were fed in standard propylene cages and ac-
climatized for 7 days to animal house conditions in an air-conditioned room, (temperature 22 
± 3 °C), relative humidity 46–70 %, 12:12 h light/dark cycle, adequate cross-ventilation), in 
accordance with the Ethical Committee (Ref. 36/2014). Fasting animals were deprived of food 
for at least 16 h but had free access to drinking water. Rats were sacrificed by cervical disloca-
tion to obtain the pancreatic islets. Collagenase (0.8 mg mL–1) dissolved in Hank’s buffered 
salt solution (HBSS) was injected into numerous lobes of the pancreas; the pancreas was then 
removed and digested for 15 to 20 min at 37 °C. Islets of Langerhans within the pancreas were 
collected by centrifugation three times with cooled HBSS at 5 °C, at 1000 rpm for 1 min (18). 
A previous study has reported that insulin receptors on rat pancreatic islets bind to human 
insulin in a similar fashion as pork insulin (11). Immediately after the collection of islets, 
another batch of MIPs was prepared. The freshly isolated islets (about 100 islets) were incu-
bated in 10 mL of PBS (pH 7.4) containing insulin (35 mg) at room temperature for 20 min, 
followed by the addition of MAA, HEAA, MBAA, and PCL-T under continuous stirring. 
Upon addition of AIBN, polymerization occurred and the islet-bound insulin-imprinted 
polymers (MIPs) were collected in a similar way to that described previously.
Particle size and z potentials
Average particle sizes and the z potential of MIP/NIP nanoparticles were determined 
using a Nanoparticle Analyzer (Zetasizer Nano ZS; Malvern Instruments Ltd., UK). Par-
ticle size was measured using the dynamic light scattering (DLS) technique. The samples 
were dispersed in PBS (pH 7.4; 0.2 mg mL–1), followed by filtration through a 0.45 μm filter 
and were then ultrasonicated for 10 min at room temperature. Measurements were carried 
out at an angle of 90° at 25 °C. For z potential measurements, the samples were diluted in 
Milli-Q water. Each sample was analyzed in triplicate.
Morphological observations
Surface morphology of MIP nanoparticles was examined by scanning electron micros-
copy (SEM Quanta 400; FEI, Brno, Czech Republic). The sample was placed on an alumi-
num stub and coated with gold using a sputter coater in an argon atmosphere for 120 s. 
TEM was used to observe MIPs after removal of the template applying an established wash-
ing protocol in the preparation process. For TEM measurements, the particles in PBS were 
dropped onto a carbon-coated copper grid and then observed with a JEM 2100F (Japan).
Pore size distribution and surface area analysis
Pore size distribution and surface areas of washed polymers were determined using 
the Brunauer-Emmett-Teller (BET) analysis with an automated gas sorption system (Quanta-
chrome Autosorb-1, USA). Relevant information was obtained as follows: the pore size and 
porosity data were obtained from a plot of pore size versus incremental pore volume to give 
the pore size distribution using the Barrett-Joyner-Halenda (BJH) method. A plot of pore 
size versus pore volume gave the total pore volume with an indication of the surface areas 
and total pore volumes of the polymers. In addition, the incremental volume that was de-
pleted with changes of each pressure was determined by the change in capacitance of the 
stem. The intrusion volume was recorded for the respective pressure or pore size.
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AFM and AFM-confocal Raman spectroscopy
In this study, the topography and surface geometry of the particles were examined by 
the combined method of AFM and Raman spectroscopy, because the environmental con-
ditions can affect the interaction of particles and biological entities in different ways of 
drug release. Non-contact mode AFM (SPA-400-SPI4000; Seiko Instrument, Inc., Japan) was 
used to test the assembly and morphology of the nanostructure. A silicone cantilever with 
a spring constant of 12 N m–1 was employed. Topographic and phase images were col-
lected at a scan rate of 1 Hz under ambient laboratory conditions. The images were further 
analyzed by the Nano Navi SPA400 (DFM) software. Raman spectra were collected with 
an AFM-confocal Raman spectrometer (NT-MDT model, Moscow, Russia) and NTEGRA 
Spectra equipped with hybrid mode (HD-AFM). The 632.8 nm excitation wavelength of a 
diode laser was focused onto the sample with a dry objective lens of 100× of 0.95 numerical 
aperture number (NA). The Stokes-shifted Raman scattering was recorded with 1200 grove 
min–1 grating using a Peltier-cooled charged-coupled device (CCD; Andor Technology 
PLC, CA, USA).
Protein adsorption experiments
Protein adsorption experiments on MIPs and NIPs were performed in PBS (pH 7.4). 
The respective polymers (5 mg) were suspended in 5 mL of different insulin solutions in 
concentrations that ranged from 5 to 30 μg mL–1 at room temperature. After filtration with 
cellulose acetate (CA) membrane filters (25 mm, 0.45 μm; Vertical Chromatography Co., 
Ltd., Bangkok, Thailand), the supernatant was analyzed using a Carry 60 UV-Vis spectro-
photometer (Agilent Technologies) at a wavelength of 272 nm, since this would not inter-
fere with the solvent and the excess of the matrix upon incubation with the polymer. The 
amount of the specifically and/or non-specifically adsorbed insulin in the polymers and 
the polymer matrix was calculated using the formula:
 Q = (Co – C) ´ V / 1000 ´ W (1)
where Q is the amount of adsorbed insulin (mg g–1); Co and C are the initial and final con-
centrations of insulin (μg mL–1), respectively; V is the volume of the solution (mL); and W 
is the polymer mass (g) (19). Each experiment was repeated three times. The binding pa-
rameters were determined from the Scatchard equation:
 B / F = (Bmax – B) / Kd (2)
where Kd and Bmax are the equilibrium dissociation constant and the apparent maximum 
number of the binding sites, respectively. The amounts of insulin adsorbed (B) were ob-
tained from absorbance determination. F represents the amount of insulin remaining in 
the supernatants. Adsorption kinetic experiments were carried out by adding 10 mg poly-
mer to 50 mL of a 10 μg mL–1 insulin solution in PBS solution at room temperature. The 
amounts of adsorbed protein on MIP/NIP nanoparticles were then evaluated with a UV-
Vis spectrophotometer, as mentioned earlier. Bomb calorimetry using Isoperibol bomb 
calorimetry (IKA® Calorimeter System C5000 Control, Germany) was used to determine 
the gross heating value of the polymer incubated with insulin.
154




The in vitro release of the protein was studied by carrying out the adsorption of insu-
lin onto the MIP and NIP nanoparticles with an initial insulin concentration of 100 μg mL–1 
at 37 °C in PBS (pH 7.4). After incubation, the nanoparticles were collected by centrifuga-
tion at 10,000 rpm for 20 min. The samples (centrifuged) were then dispersed in buffer 
solutions of pH 1.2 and pH 7.4 at 37 °C. At specific time intervals, the amounts of insulin 
released in the supernatant were assayed by UV-Vis analysis following centrifugation (16). 
Experiments were performed in triplicate.
In vivo evaluation
Male Wistar rats (200–250 g) were obtained from the Southern Laboratory Animal 
facilities of the Prince of Songkla University, Thailand (Ethical No. 36/2014). Diabetes was 
induced in rats by an intraperitoneal injection of streptozotocin (35 mg kg–1) dissolved in 
citrate buffer (pH 4.5) (20). After 3 days of injection, rats were considered to be diabetic 
when the glycaemia was above 250 mg dL–1. The animals were fasted overnight (water ad 
libitum) and remained fasted during the whole experiment. There were seven groups of 
animals, each group containing five diabetic rats. The first two groups of rats were given 
orally MIP1 (170 mg kg–1, single monomer MAA) and MIP2 (150 mg kg–1, mixed functional 
monomer MAA and HEAA) loaded with insulin (50 IU kg–1). The rats of the next two 
groups were administered orally the respective NIP nanoparticles loaded with insulin (50 
IU kg–1). The fifth group received an insulin solution orally (50 IU kg–1). The rats of the 
placebo control group were orally administered MIP nanoparticles (without insulin). In-
sulin formulation alone was given subcutaneously (1 IU kg–1) to the last group of rats. 
Blood samples were collected from the tail vein and the blood glucose level was measured 
using a glucose meter (Accu-Chek® Performa; Roche Diagnostics GmbH, Germany) at pre-
determined time points. Pharmacological bioavailability (PA %) of insulin-loaded nanopar-
ticles after oral administration was calculated according to the following formula (21):
 PA (%) = ([AAC]p.o. / [AAC]s.c.) ´ (Doses.c. / Dosep.o.) ´ 100 (3)
where [AAC]p.o. and [AAC]s.c. represent the area above the blood glucose level-time curve 
of oral and subcutaneous insulin formulation, respectively, and Dosep.o. and Doses.c. are the 
oral and subcutaneous doses given. AAC were calculated by applying the trapezoidal rule 
(22). One-way analysis of variance (ANOVA), followed by Tukey’s test, was used for statis-
tical analysis; p < 0.05 was considered to be statistically significant.
RESULTS AND DISCUSSION
Synthesis and characterization of MIPs
In this report, we chose molecular imprinting to investigate the recognition of phar-
maceutically active insulin (F1) and rat islet-bound insulin (F2) as templates. Scheme 1 
gives a schematic representation of the recognition of the insulin molecule at a binding 
pocket site prepared by aqueous precipitation polymerization. Varying the amount of 
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MBAA as well as the concentrations of MAA and HEAA (Table I) led to the formation of 
MIPs, resulting in insulin affinity to the binding sites within the polymer matrix. MIP1 
contains a single functional monomer (MAA) with high cross-linking whereas MIP2 com-
Scheme 1.
Table I. Polymeric composition of MIPs and NIPs nanoparticles
Compd. 











MAA 1.6 5.0 1.6 5.0 1.6 5.0
HEAA – 2.0 – 2.0 – 2.0
MBAA 8.5 3.2 8.5 3.2 8.5 3.2
PCL-T 0.05 0.05 0.05 0.05 0.05 0.05
AIBN 0.04 0.04 0.04 0.04 0.04 0.04
ne bold u slici
156
P. Kumar Paul et al.: Biomimetic insulin-imprinted polymer nanoparticles as a potential oral drug delivery system, Acta Pharm. 67 
(2017) 149–168.
 
Fig. 1. a) and d) SEM, b), c), e) and f) TEM images of insulin and insulin imprinted polymers. e) the 
surface morphology of insulin. b) and f) TEM images showing the more porous structure of MIP than 
that of NIP (c). Micrograph A represents the rough surface of MIP compared to NIP (d). g) Nitrogen 
adsorption/desorption isotherms of MIPs compared to NIPs.
a)                                                               b)                                            c)
d)                                                               e)                                            f)
g)
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prises two functional monomers (MAA and HEAA) with lower cross-linking. MIP3 and 
MIP4 are similar to MIP1 and MIP2, except for the different insulin source (pharmaceutical 
company). Sizes obtained from the light scattering measurements are shown in Table II. 
Clearly, a slight decrease in particle size was observed, which was associated with an in-
crease in the functional monomer concentration and the addition of a second monomer 
(HEAA) resulting from the interaction between the protein template and the surrounding 
monomers during polymerization.
SEM and TEM were used to examine the surface morphology and nanoparticle size 
of the formed MIP nanoparticles (Fig. 1a–e). In both SEM (Fig. 1a) and TEM (Fig. 1b), MIPs 
exhibited greater roughness and porous morphology than NIPs (Fig. 1d and c) due to the 
interaction of insulin with the functional monomer, which was finally washed out after 
polymerization. Further, the light scattering data of MIP nanoparticles revealed particle 
size ranges from 200 to 220 nm. This was confirmed by TEM observations, as shown in Fig. 
1b-f. The optimum size ranged from 50 to 500 nm for the interaction between nanoparticles 
and epithelial cells (23). Therefore, MIPs could be suitable candidates for the transport of 
insulin across the cell membrane.
It is noteworthy that the PDI values of approximately 0.3 were found in all cases of 
MIPs. In contrast, NIP nanoparticles showed a higher PDI value of about 0.4 with higher 
particle size ranges from 230 to 300 nm. The results indicated the effect of template protein 
on the formation of MIP nanoparticles with homogeneous dispersion during the poly mer-
ization process. Although no template was added for NIP during polymerization, this 
 resulted in a slightly broader size distribution compared to MIP. The z potentials of all 
imprinted nanoparticles were negative, as shown in Table II. As can be seen, MIPs pro-
duced with a mixed functional monomer had a lower surface charge than their corre-
sponding NIPs, whereas the single functional monomer in F1 and the control polymer 
showed no differences in particle surface charges. The z potential of F1 was found slightly 
increased, whilst there was a relatively higher z potential value of MIP3 of F2 than of F1. 
This led to an increase in accessibility of the biotherapeutic molecule to the binding site 
Table II. Characteristics of the insulin imprinted nanoparticles
Polymer 















MIP1 221.86 ± 23.55 0.39 ± 0.03 –32.2 ± 5.1 200.46 ± 7.8 0.37 ± 0.01 –28.1 ± 3
MIP2 198.73 ± 3.05 0.33 ± 0.02 –32.3 ± 4.23 195.03 ± 3.11 0.34 ± 0.05 –24.8 ± 2.48
MIP3 214.56 ± 24.54 0.38 ± 0.05 –19.7 ± 3.21 199.13 ± 9.36 0.33 ± 0.02 –29 ± 3.26
MIP4 199.73 ± 5.9 0.34 ± 0.01 –30.4 ± 4.1 194.6 ± 8.17 0.35 ± 0.01 –31 ± 4.1
NIP1 302.46 ± 10.5 0.46 ± 0.08 –28.9 ± 3.7 204.13 ± 5.09 0.37 ± 0.02 –29.1 ± 3.4
NIP2 236.56 ± 31.33 0.43 ± 0.05 –33.6 ± 2.3 201.1 ± 16.21 0.35 ± 0.02 –29.8 ± 2.77
 a PDI – polydispersity index; mean ± SD (n = 3).
158
P. Kumar Paul et al.: Biomimetic insulin-imprinted polymer nanoparticles as a potential oral drug delivery system, Acta Pharm. 67 
(2017) 149–168.
 
within the MIP; hence higher adsorption for MIP3 (2.69 mg g–1). This result could be ex-
plained by the presence of zwitterionic molecules on the nanoparticles, caused by the 
bound insulin and N-linked glycoproteins on the rat b cells that self-assembled some 
structural motifs into polymer F2 (24, 25). The negative surface charge of MIPs varied be-
tween –20 and –33 mV and contained the hydrophilic functionalities on the MIP binding 
sites and the negatively charged side chains. The generation of insulin MIP nanoparticles 
in this study involved two point interactions of the insulin with the MAA and HEAA as a 
mixed functional monomer, forming an interaction with each of the amine and carbonyl 
moieties of the islets that would cause a strong interaction with the complementary tem-
plate, hence expected the MIP show the intrinsic b cells-bound insulin template. Further-
more, this negative surface charge could allow them to diffuse into the mucus as a result 
of less interaction with the mucin (26, 27).
Surface area and pore size distribution of insulin MIPs
Macroscopic characteristics of MIPs and NIPs were examined by pore analysis such 
as the surface area, pore volume, and pore diameter of all of the synthesized materials. In 
supplemental data (Table S1), the mixture of a larger amount of the two monomers in MIP2 
(MAA and HEAA) showed a larger surface area (149.1 m2 g–1), whereas a bigger quantity of 
the cross-linker (MBAA) generated a smaller surface area (21.83 m2 g–1) for MIP1. A similar 
trend was observed for MIP3 and MIP4. A large surface area of particles would lead to 
smaller particle sizes. BET analysis also demonstrated the presence of mesopores of about 
20 nm for the polymer, leading to similar characteristics to those of a type IV isotherm, so 
their nanospace pores can be distinguished from NIPs. In the case of NIPs, the pore diam-
eter was larger and the isotherm exhibited a type III curve characteristic due to the non-
porous structure with low interaction (28). That insulin recognition sites formed within 
the nanospace pores was further corroborated by a bomb calorimeter. After incubation 
with insulin (suspension formulation, Novo Nordisk Pharma, Thailand), the gross heating 
value was almost similar for both MIP and NIP (see Table S2). Evidently, with insulin 
(crystalline powder form, Sigma-Aldrich, USA), the gross heating value was 16,844 J g–1 for 
MIP2 and 13,518 J g–1 for NIP2. This differential energy proved self-organization of the 
polymer in the medium that formed the biomimetic system. This result indicates the ab-
sence of surface adaptations of peptides after the template removal.
AFM studies
Fig. 2 shows the AFM image of the fine structure of insulin over the surface near the 
closely packed barrier of the nanoparticles for MIP1. It can be seen that there was a cloud-like 
blanket for MIP1, F1 (see Fig. 2f), and the distance between the interval of the neighboring 
nanoparticles and the individual pores was much smaller compared to that of the NIP1. The 
AFM image of the imprint with islets (MIP2) showed particle floccules, a worm-like cavity 
due to elastic interaction, and a larger overlap of surface coverage that resulted from adhe-
sion of the induced association of the protein on the polymer to extend more, so that it was 
difficult to distinguish in the AFM image, as shown in Fig. 2f. The nanoscale contact geom-
etry of the cavities was measured and found to be 2 ´ 25 ´ 25 nm (height ´ length ´ width) 
for MIPs, as shown in Fig. 3a–e. According to the protein database, the size of the insulin 
hexamer is 3.5 ´ 5 nm and contains Zn as a coordinating atom (29). The three-dimensional 
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structure of both MIP1 (Fig. 3b) and MIP2 (Fig. 3c) indicates that they can accommodate the 
template protein with a size of the remaining cavity similar to the surface and possibly the 
geometrical change of the imprinted materials. Larger size of the cavity was observed for 
either the NIP1 (Fig. 3d) or NIP2 (Fig. 3e), each showing a shallow pore on the surface. Evi-
dently, the AFM images confirmed successful generation of synthesized MIP nanoparticles 
after removal of the protein that formed the accommodated bionanomaterial inside the 
nanopore on the resultant synthetic materials. This was also related to insulin geometry.
Fig. 2. a) Non-contact mode AFM of insulin, b) and c) surface topography of MIPs, d) and e) NIPs. This 
indicates the functionality of protein imprint after removal of the template. b) and d) represent F1 and 
c) and e) F2. f) AFM images of the colloidal patterns and 2D topography of the polymer surface with 
individual internal structures.
a)                                                        b)                                                 c)
 








We used confocal Raman spectroscopy to evaluate the structural information of bio-
logical entities in the protein template that remained in the synthesized nanoparticles. Fig. 
3f illustrates the surface-enhanced Raman-AFM of the insulin and MIPs, showing differ-
ent functional groups of interaction with the template that had an insulin imprint. The 
MIPs show the cluster of ridges and the grooves in the AFM image, which isolated a diam-
eter of ~5 nm of an active trench attached to the structure of the nanoparticle surface. Table 
III shows Raman data obtained from the AFM-Raman studies for insulin and polymers. 
Fig. 3. AFM images of the imprinted cavity remaining after template removal. a) the nanoscale contact 
geometry of insulin molecule, b) and c) the imprinted cavities for MIP1 and MIP2, d) and e) the im-
printed cavities for NIP1 and NIP2. b) and d) F1, c) and e) F2. Below: The difference between the im-
print pattern and internal structure of insulin on the surface of nanoparticles. f) Raman spectra of 
insulin and MIPs with their corresponding NIP.
a)                                                        b)                                                 c)
 
                                                           d)                                                 e)
 
                                                           f)
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The selected insulin in the Raman spectra was found at a different wave number, for ex-
ample, tyrosine (Tyr) at 832 cm–1, phenylalanine (Phe) at 1010 cm–1, and the 1215 cm–1 band 
for Tyr and Phe residues outside the polymer cross-linked chains, which is well known to 
be characteristic for R6 conformation of hexameric human insulin (29). The Raman shift at 
1010 cm–1 can be used to confirm the intrinsic property of insulin formulation in the na-
noscale environment of MIP1 (Fig. 3f). In contrast, the present method of generating the 
nanotopography for MIP2 was made to inhibit the Tyr and Phe residues in Raman spectra, 
allowing for the gap size of the captured surface to be probed. However, the oriented in-
sulin indicated the structure and direction of peptide changes upon the template binding 
for MIPs. Dynamically, there was a far better interaction of the bulk layer of insulin than 
that of insulin in the pancreas islets with the MIP layer, which clearly showed the absence 
of a Raman peak shift for the islet imprint. For both NIPs, the spatial motifs of the insulin 
template were not fully distinguishable from the Raman shift.
Recognition ability of insulin MIPs
The recognition ability of the template for both the insulin-imprinted polymers and 
the corresponding NIPs was examined by batch binding experiments. Figs. 4a and b show 
the adsorption kinetic process of the protein to MIP and NIP nanoparticles. It can be seen 
that the MIPs of all formulations exhibited much higher adsorption capacities. Almost 
80 % of equilibrium adsorption was achieved within 30 min and reached a steady-state for 
adsorption at around 2 h for both the F1 and F2 formulations. This was attributed to the 
high recognition efficiency of the template protein for the imprinting sites because of the 
nanoscale sizes of the imprinted cavity fitting to template structure through better diffu-
sion properties (17). In contrast to NIPs, the adsorption of insulin was lower than that for 
MIPs due to the imprinting process. In addition, MIP2 showed a comparatively higher 
adsorption capacity than MIP1 for insulin, which was apparently different from that of 
MIP2, so a smaller amount of cross-linker contributed more than in the single monomer, 
as reported by previous studies (30). From the protein adsorption data, it is clear that MIPs 
adsorbed insulin more efficiently than NIPs. Between the two different mole ratios – a low 
mole ratio of MBAA containing the HEAA copolymer produced a relatively high density 
of binding sites, whereas a high mole ratio of cross-linkers and MAA lowered the imprint-
ing efficiency of MIPs (31). This can be attributed to the different ratio of the amino acid-
surface insulin on the imprinted cavities allowed for recognition sites, emphasizing the 
importance of the initial flexible conformation of protein (32).
Table III. Raman data of the insulin and polymers
Raman peak Raman shift (cm–1)
Peak intensity
Insulin MIP1 MIP2 NIP1 NIP2
Tyrosine (Tyr) 832.53 464.38 330.25 45.56 306.33 250.92
C-C 940.24 307.84 279.05 66.66 175.59 162.64
Phenylalanine (Phe) 1010.98 369.50 332.96 85.14 133.21 164.16
Tyr and Phe 1215.25 1005.62 743.97 154.27 470.31 421.45
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The recognition behavior, which was dependent on the concentration of insulin in 
solution, was investigated to obtain the binding isotherm using insulin in a pH 7.4 buffer 
solution. The binding isotherm curves (Fig. 4c and d) show that the adsorption capacity of 
MIP nanoparticles was increased with an increase in the initial concentration of insulin in 
comparison with NIPs. Maximum adsorption capacity was obtained by MIP2 for both F1 
and F2 formulations (3.26 and 3.34 mg g–1, respectively). The Scatchard plots of insulin 
binding to MIP1 and MIP2 nanoparticles are shown in the insets (Fig. 4c and d) and the 
binding parameters are given in Table S3. This revealed a single straight line and implied 
the presence of homogeneous binding sites in the polymers (33). The equilibrium disso-
ciation constant of insulin (Kd) of insulin binding to MIP2 (3.049 μmol L–1) was somewhat 
higher than MIP1 (1.914 μmol–1), whereas the number of binding sites (Bmax) was almost the 
same (4 μmol g–1) and clearly indicated the formation of uniform recognition sites (34).
In vitro release studies
To understand how the fluid environment affected the attached surface of the poly-
mers, insulin release was performed under gastric and intestinal conditions (pH 1.2 and 
Fig. 4. a) Adsorption kinetic curves of MIPs and NIPs of F1 and b) F2 formulation at 25 °C (pH = 7.4); 
c) Binding isotherm curves of MIPs and NIPs of F1 and d) F2 formulation at 25 °C (pH = 7.4). Insets: 
Scatchard plot of insulin binding to MIP1 and MIP2 nanoparticles in PBS (pH = 7.4).
a)                                                                          b)
c)                                                                          d)
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7.4). At different pH values, the insulin release rate from MIPs for both F1 and F2 varied 
greatly compared to their corresponding NIPs. For MIPs at pH 1.2 (Fig. 5a), insulin release 
was retarded and less than 30 % of insulin was released, whereas, at pH 7.4, almost 90 % 
of insulin was released from MIPs (Fig. 5c). In contrast, the release profiles of insulin from 
NIPs at both pH values were almost the same, about 90 %. This could be attributed to the 
absence of recognition sites in NIPs, which resulted in low interaction with the insulin and 
its subsequent release to the external medium (35). In basic medium (pH 7.4), a gradual 
release of insulin from MIPs (30–40 % in the first 30 min) was observed, followed by sus-
tained release (Fig. 5c and d). MIP2, which was produced by mixed functional monomers 
(MAA and HEAA) with a lower degree of cross-linkage, provided a considerably faster in 
vitro release (k = 7.35 ± 0.89) than MIP1 (k = 4.73 ± 2.57). MIP2 has a larger amount of MAA 
than MIP1 and offers a higher magnitude of solvated matrix, resulting in higher insulin 
release at basic pH. In addition, better insulin release from MIP2 nanoparticles was further 
supported by a greater Kd value of MIP2 (3.049 μmol L–1) than that of MIP1 (1.914 μmol L–1). 
Drug release data at pH 7.4 were analyzed by the Korsmeyer-Peppas equation as follows:
 Mt / M∞ = k tn (4)
where Mt/M∞ is the fraction of insulin released at time t and k is the release rate constant. 
The diffusion exponent n characterizes the release mechanism of the drug depending on 
the geometry of the material tested. For radial geometry, n = 0.45 corresponds to the Fick-
Fig. 5. Release profiles of insulin from MIPs and NIPs at pH 1.2: a) of formulation F1 and b) of F2; 
Release profiles of insulin from MIPs and NIPs at pH 7.4: c) of formulation F1 and d) F2.
a)                                                                          b)
c)                                                                          d)
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ian transport, 0.45 < n < 0.89 corresponds to the non-Fickian (anomalous) transport, and 
n = 0.89 is related to the case II transport (36). The diffusion exponent (n) values of MIP1 
and MIP2 were found to be between 0.45 and 0.89 (see Table S4), implying non-Fickian 
transport. The results indicated a higher mode of insulin release in aqueous medium ow-
ing to the reduced mass transfer resistance of the protein in the imprinted matrix. The 
effect of the polymer mixture in this work was in agreement with the previous study of 
MAA and in the polyethylene glycol-based hydrogel (37, 38) enabling the interaction with 
the receptor on the membrane subsequent to insulin release to the medium. Nonetheless, 
the proximity of the protein receptor or the dense packing of the amino acid groups af-
fected the insulin structure within imprints, as determined by confocal Raman spectros-
copy, favoring the interaction of the insulin at its binding site surrounded by the cross-
linked chains. Thus, they have different affinities for a significant proportion of dormant 
molecules upon exposure to the environment, and the underlying porous network main-
taining the structural stability resulted in significant effects on protein release.
Fig. 6. Percentage reduction in blood glucose levels of diabetic rats after oral administration of insulin 
loaded MIPs and NIPs at a dose of (50 IU kg–1), or after subcutaneous injection of insulin solution at 
1 IU/kg (n = 5). *Statistically significant difference from the corresponding NIPs. Top: The proposed 
mechanism of delivery of insulin with biomimetic insulin-MIP by the transcellular nanoparticle 
transport mechanis
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In vivo studies of insulin-loaded nanoparticles on diabetic rats
Fig. 6 shows the blood glucose level-time profiles after oral administration of the in-
sulin-loaded MIPs to diabetic rats. As can be seen, there was a sharp reduction in the blood 
glucose level (60 % within 2–3 h) after the subcutaneous injection of the free form of insu-
lin (INS-SC) at a dose of 1 IU kg–1; subsequently, the blood glucose level returned to its 
basal level with time. No obvious hypoglycemic effect was observed for the insulin solu-
tion (INS-oral) and the placebo control group (MIP1-blank) or either of the control poly-
mers. After administration of both NIP nanoparticles loaded with insulin (INS-NIP1 and 
INS-NIP2) orally (50 IU kg–1), there was no change in the blood glucose level, which showed 
superimposable reductions of blood glucose level in all cases. In contrast, the blood glu-
cose level was reduced markedly after oral administration of the insulin-loaded MIPs (50 
IU kg–1). In comparison with both MIPs (INS-MIP1 and INS-MIP2), MIP1 showed the high-
est blood glucose level (39 % in 4 h) before gradual reduction, which lasted up to 12 h, 
whereas MIP2 reduced the initial blood glucose level significantly (p < 0.05; by 44 % with-
in 4 h) and the blood glucose level was maintained at this level for up to 12 h. These results 
indicated that the distribution of insulin-MIP was unaffected by the GI environment due 
to the stabilization of insulin by MIPs after oral administration.
The parameters of plasma glucose levels are given in Table IV, and at a dose of 50 IU 
kg–1, the relative pharmacological bioavailability in the percentage reduction of glucose of 
MIP1 and MIP2 was 1.73 and 1.55 %, respectively. In addition, the difference in the loading 
capacity between MIP2 and NIP2 was found to be 55.75 and 20.87 mg insulin/g nanopar-
ticles, respectively (Table S5). The loading capacity of MIPs was almost threefold higher 
than that for NIPs. As opposed to the nanoparticulate MIPs loaded with insulin, NIP failed 
to reduce the blood glucose level, due to the lack of specific binding sites within the poly-
mer, resulting in no protein affinity. There was further improvement in insulin absorption 
in the case of MIP2 over MIP1, which was clearly observed because of the effect of insulin 
on the lipid-protein layer. The results showed that it increased the interactions of the bio-
molecule at the spatial motifs of the insulin template into the biological milieu in rat, that 
mimicked the insulin-cell surface interaction (39). This could be ascribed to the surface of 
MIP2 enabling surface adhesion of insulin-MIPs with a dense set of nanoscale pores. Oral 
administration of the insulin loaded MIPs to diabetic rats displayed a more significant 
Table IV. Relative pharmacological bioavailability and parameters of plasma glucose levels (n = 5)
Parameter INS-MIP1 INS-MIP2 INS-SC
Insulin dose (IU kg–1) 50 50 1
Cmina (mg dL–1) 61.58 ± 10.57 54.65 ± 9.43 40.76 ± 11.65
tminb (h) 4 4 2
AAC 1577.71 ± 208.29 1422.88 ± 254.90 1816.2 ± 188.96
PA% 1.74 1.55 100
a Cmin, minimum plasma glucose concentration (% of initial)
b tmin, time at which Cmin is attained; AAC, area above the blood glucose level-time curves; PA%, relative pharma-
cological bioavailability.
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hypoglycemic effect than that of NIPs. Based on these important findings, we proposed 
insulin transport through the transcellular pathway (Fig. 6, top), related to the particle 
size, surface charge, and mucous adhesion in the GI tract, which would facilitate oral pro-
tein delivery. However, further investigations are required to make conclusions about the 
transport mechanisms.
CONCLUSIONS
We have successfully produced selective particles incorporating insulin and insulin-
bound islets by the molecular imprinting of protein on nanoparticles using the precipita-
tion polymerization method. Biomimetic MIPs nanoparticles can serve as potential insulin 
oral delivery systems and represent a new way for an alternative platform, especially be-
cause of their robust physical structures, biocompatibility and loading capabilities. The 
MIPs exhibited much higher affinity toward the insulin with rapid adsorption kinetics, 
which enabled them to selectively deliver the therapeutic agent. The application of MIPs 
showed a different response of the blood glucose level, depending on the variation in the 
ratio of the functional monomer and cross-linkers. Targeted delivery of biomolecule rec-
ognition-based therapies such as insulin using the molecular imprinting approach could 
be effective for improvement of its therapeutic efficiency.
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MIP1 21.83 0.089 14.82 134.50 0.340 10.12
MIP2 149.1 0.462 12.40 212.60 0.581 10.94
NIP1 27.39 0.263 38.02 39.81 0.257 25.85
MIP3 90.77 1.415 22.36 111.60 0.634 22.74
MIP4 189.7 0.845 17.72 252.50 0.772 12.24
NIP2 86.85 1.031 47.50 47.44 0.276 23.24
Table S2
Polymer 
Gross heating value (J g–1)






Formulation Kd (μM) Bmax (μmol g–1) R2 
MIP1 1.91 ± 0.18 4.05 ± 0.15 0.997
MIP2 3.05 ± 0.43 4.34 ± 0.29 0.995
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Table S4
Formulation n* k* r2 
MIP1 0.536 ± 0.122 4.74 ± 2.57 0.977
MIP2 0.451 ± 0.028 7.36 ± 0.90 0.998
* For mean ± SD (n = 3).
Table S5
MIP1 MIP2 NIP1 NIP2
Loading capacity (mg g–1) 42.51 55.75 18.53 20.87
Loading efficiency (%) 78.94 82.13 47.01 50.81
